Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:TEVA
|
| gptkbp:activities |
modulates immune response
|
| gptkbp:approves |
gptkb:United_States
|
| gptkbp:brand |
gptkb:Copaxone
|
| gptkbp:category |
gptkb:unknown
B |
| gptkbp:class |
immunomodulator
|
| gptkbp:clinical_trial |
Phase III
symptomatic treatment long-term therapy |
| gptkbp:contraindication |
hypersensitivity to glatiramer acetate
|
| gptkbp:dosage_form |
gptkb:software_framework
20 mg daily 40 mg three times a week |
| gptkbp:education |
storage instructions
injection technique side effects awareness importance of adherence when to seek medical help |
| gptkbp:effective_date |
gptkb:1996
|
| gptkbp:formulation |
injectable
|
| https://www.w3.org/2000/01/rdf-schema#label |
Copaxone
|
| gptkbp:indication |
gptkb:relapsing_forms_of_multiple_sclerosis
|
| gptkbp:ingredients |
glatiramer acetate
|
| gptkbp:interacts_with |
none significant
|
| gptkbp:invention |
gptkb:2015
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:is_used_for |
gptkb:psychologist
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
gptkb:Company
|
| gptkbp:marketed_as |
Glatopa
|
| gptkbp:pharmacokinetics |
subcutaneous absorption
immune modulation |
| gptkbp:previous_name |
gptkb:battle
|
| gptkbp:price |
varies by region
|
| gptkbp:research_focus |
combination therapies
safety profile new formulations long-term efficacy |
| gptkbp:safety_features |
monitor for allergic reactions
monitor for signs of infection not for use in patients with active infections not for use in patients with severe liver disease |
| gptkbp:side_effect |
anxiety
dizziness fatigue headache nausea fever chest pain rash injection site reactions palpitations |
| gptkbp:storage |
refrigerated
|
| gptkbp:traded_on |
gptkb:Copaxone
|